Current Research and Scholarly Interests
Dr. Muffly is the Principal Investigator on numerous clinical trials in the Division of BMT-CT. Her trials have included novel CAR T-cell constructs for adults with ALL and AML, including CAR T-cell therapies that have been developed and manufactured at Stanford. She has studied methods to improve CAR T-cells in adults with ALL in vivo through the use of cytokine and tyrosine kinase inhibitors. She is also interested in novel trials and approaches to transplantation, and is the Principal Investigator of an investigator initiated trial that combines a donor grant engineered transplant with allogeneic CAR T-cells for adults with high-risk ALL. She has several industry partnerships to advance science and new therapeutics in these patient populations. Aside from clinical trials, she leads a health outcomes research program that has received successive funding to study equity in access to care for young adults with acute leukemia. She has published several papers on this topic and works with researchers around the country examining large datasets to determine patterns of care and barriers to specialized cancer care. She has mentored dozens of students and trainees and serves as faculty for mentorship programs (ASH CRTI). She is also a current or past member of the Editorial Boards of Blood, Blood Advances, the Hematologist, and serves as the Executive Editor of Hematology, the ASH Annual Meeting Book.
